Official Title
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Brief Summary

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Approved for marketing
Treatment IND/Protocol
Relapsed or Refractory Mantle Cell Lymphoma

Drug: Ibrutinib

Ibrutinib

Eligibility Criteria

Inclusion Criteria:

- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or
refractory disease after prior therapy are eligible.

Exclusion Criteria:

- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
not eligible.

- Patients previously treated with ibrutinib are not eligible.

- Patients enrolled in another interventional clinical study with therapeutic intent are
not eligible.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Brazil
Puerto Rico
United States
Locations

Phoenix, Arizona, United States

Duarte, California, United States

La Jolla, California, United States

Los Angeles, California, United States

Stanford, California, United States

Denver, Colorado, United States

Norwalk, Connecticut, United States

Stamford, Connecticut, United States

Washington, District of Columbia, United States

Brandon, Florida, United States

Miami Beach, Florida, United States

Ocala, Florida, United States

Orlando, Florida, United States

Palm Beach Gardens, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Springfield, Illinois, United States

Goshen, Indiana, United States

Sioux City, Iowa, United States

Lexington, Kentucky, United States

Louisville, Kentucky, United States

Metairie, Louisiana, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Worcester, Massachusetts, United States

Ann Arbor, Michigan, United States

Detroit, Michigan, United States

Rochester, Minnesota, United States

Jefferson City, Missouri, United States

Saint Louis, Missouri, United States

Lincoln, Nebraska, United States

Omaha, Nebraska, United States

Reno, Nevada, United States

Hackensack, New Jersey, United States

New Hyde Park, New York, United States

New York, New York, United States

Syracuse, New York, United States

Durham, North Carolina, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Hershey, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Watertown, South Dakota, United States

Knoxville, Tennessee, United States

Nashville, Tennessee, United States

Austin, Texas, United States

Dallas, Texas, United States

Houston, Texas, United States

Lubbock, Texas, United States

Burlington, Vermont, United States

Charlottesville, Virginia, United States

Morgantown, West Virginia, United States

Madison, Wisconsin, United States

Barretos, Brazil

Florianopolis, Brazil

Porto Alegre, Brazil

Rio De Janeiro, Brazil

Salvador, Brazil

Sao Paulo, Brazil

San Juan, Puerto Rico

Pharmacyclics LLC.
NCT Number
Keywords
Mantle Cell Lymphoma
Ibrutinib
MeSH Terms
Lymphoma
Lymphoma, Mantle-Cell